


This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1. (currently amended) A compound of formula (I) or a pharmaceutically acceptable salt or ester thereof:



wherein

R is a C₁₋₁₆ straight or branched-chain alkyl, optionally substituted by C₃₋₇cycloalkyl; provided that the compound is not:

- a) 3,4,5-piperidinetriol, 1-butyl-2-(hydroxymethyl)-, (2S,3R,4R,5S);
 - ~~b) 3,4,5-piperidinetriol, 1-phenylmethyl-2-(hydroxymethyl)-, (2S,3R,4R,5S);~~
 - ~~b)e) 3,4,5-piperidinetriol, 1-nonyl-2-(hydroxymethyl)-, (2S,3S,4R,5S); or~~
 - ~~c)d) 3,4,5-piperidinetriol, 1-dodecyl-2-(hydroxymethyl)-, (2S,3R,4R,5S); or~~
 - ~~e) 3,4,5-piperidinetriol, 1-(1-phenyl)ethyl-2-(hydroxymethyl)-, (2S,3R,4R,5S).~~
2. (original) A compound as defined in claim 1 wherein the hydroxyl group at position 3 is in the R configuration.
3. (canceled)
4. (original) A compound as defined in claim 3 wherein R is C₃₋₁₀ straight chain alkyl.

5. (currently amended) A compound selected from the group consisting of:

3,4,5-piperidinetriol, 1-propyl-2-(hydroxymethyl)-, (2S,3R,4R,5S)

3,4,5-piperidinetriol, 1-pentyl-2-(hydroxymethyl)-, (2S,3R,4R,5S)

3,4,5-piperidinetriol, 1-heptyl-2-(hydroxymethyl)-, (2S,3R,4R,5S)

3,4,5-piperidinetriol, 1-butyl-2-(hydroxymethyl)-, (2S,3S,4R,5S)

3,4,5-piperidinetriol, 1-nonyl-2-(hydroxymethyl)-, (2S,3R,4R,5S)

3,4,5-piperidinetriol, 1-(1-ethyl)propyl-2-(hydroxymethyl)-, (2S,3R,4R,5S)

3,4,5-piperidinetriol, 1-(3-methyl)butyl-2-(hydroxymethyl)-, (2S,3R,4R,5S)

~~3,4,5-piperidinetriol, 1-(2-phenyl)ethyl-2-(hydroxymethyl)-, (2S,3R,4R,5S)~~

~~3,4,5-piperidinetriol, 1-(3-phenyl)propyl-2-(hydroxymethyl)-, (2S,3R,4R,5S)~~

3,4,5-piperidinetriol, 1-(1-ethyl)hexyl-2-(hydroxymethyl)-, (2S,3R,4R,5S) and

3,4,5-piperidinetriol, 1-(2-ethyl)butyl-2-(hydroxymethyl)-, (2S,3R,4R,5S)

~~3,4,5-piperidinetriol, 1-[(2R)-(2-methyl-2-phenyl)ethyl]-2-(hydroxymethyl)-, (2S,3R,4R,5S)~~

~~3,4,5-piperidinetriol, 1-[(2S)-(2-methyl-2-phenyl)ethyl]-2-(hydroxymethyl)-, (2S,3R,4R,5S)~~


and pharmaceutically acceptable salts and esters thereof.

6. (previously presented) The compound 3,4,5-piperidinetriol, 1-pentyl-2-(hydroxymethyl)-, (2S,3R,4R,5S), or a pharmaceutically acceptable salt or ester thereof.

7. (previously presented) A pharmaceutical formulation comprising at least one compound of formula (I) or a pharmaceutically acceptable salt or ester thereof:

DOCKET NO.: OGS-0002
Application No.: 10/618,165
Office Action Dated: February 9, 2005

PATENT



wherein

R is a C₁₋₁₆ straight or branched-chain alkyl, optionally substituted by C₃₋₇cycloalkyl, provided that the compound is not 3,4,5-piperidinetriol, 1-nonyl-2-(hydroxymethyl)-, (2S,3S,4R,5S);

optionally together with one or more pharmaceutically acceptable carriers, excipients and/or diluents.

8-20. (canceled)